65,437 trials
Methamphetamine Dependence
Primary: Heart Rate — 79.66 beats per minute
Asthma
Primary: Number of Severe Asthma Exacerbations Per Participant. — 0.097; 0.080 Severe exacerbations per participant
Smoking
Primary: Continuous Abstinence at End of Treatment (Self-report)(Defined as the Number of Consecutive Days Without Smoking a Cigarette for Each Subject) — 83; 75 Participants
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 782.438; 738.531 ng/mL
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 272.038; 238.043 ng/mL
Respiratory Tract Infections
Primary: Number of Patients With Adverse Events (AEs) — 27 participants
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 939.025; 865.678 ng/mL
Nocturnal Vasomotor Symptoms
Primary: Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes — -19.54; -20.55; -15.99 Awakenings
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
Non-Small Cell Lung Cancer · Lung Cancer, Non-Small Cell
Primary: Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume — 2; 33 participants
Exocrine Pancreatic Insufficiency · Steatorrhea · Malabsorption Syndromes
Primary: Change in the Coefficient of Fat Absorption (COA-fat Percent) — -34.1; -1.5 percentage COA-fat — p=<0.001
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Colchicine — 2,328.44; 1,668.33 pg/mL
Visual Function
Primary: Uncorrected Visual Acuity (UCVA) — 0.06; 0.14 logMAR
Cataract
Primary: Uncorrected Visual Acuity (UCVA) — 0.05; -0.07; 0.15; 0.20 logMAR
Prostatic Hyperplasia
Primary: Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods. — 29; 27; 40; 14 events…